MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer.

Targeted therapy for metastatic diseases relies on the identification of functionally important metastasis genes from a large number of random genetic alterations. Here we use a computational algorithm to map minimal recurrent genomic alterations associated with poor-prognosis breast cancer. 8q22 genomic gain was identified by this approach and validated in an extensive collection of breast tumor samples. Regional gain of 8q22 elevates expression of the metastasis gene metadherin (MTDH), which is overexpressed in more than 40% of breast cancers and is associated with poor clinical outcomes. Functional characterization of MTDH revealed its dual role in promoting metastatic seeding and enhancing chemoresistance. These findings establish MTDH as an important therapeutic target for simultaneously enhancing chemotherapy efficacy and reducing metastasis risk.

[1]  Yibin Kang.  Functional genomic analysis of cancer metastasis: biologic insights and clinical implications , 2005, Expert review of molecular diagnostics.

[2]  A. Nobel,et al.  Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .

[3]  D. Millhorn,et al.  Bcl-2/adenovirus E1B 19 kDa interacting protein-3 knockdown enables growth of breast cancer metastases in the lung, liver, and bone. , 2005, Cancer research.

[4]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[5]  W. Hiddemann,et al.  Increase of P-glycoprotein-mediated drug resistance by hsp 90b , 1996 .

[6]  A. Zetterberg,et al.  Comparative genomic hybridization of formalin-fixed, paraffin-embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas. , 1995, Cancer research.

[7]  E. Ruoslahti,et al.  Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. , 2004, Cancer cell.

[8]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[9]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[10]  P. Comoglio,et al.  Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. , 2002, Cancer research.

[11]  M. Xiong,et al.  Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells , 2002, Oncogene.

[12]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[13]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[14]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[15]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[16]  Eric S. Lander,et al.  Genomic analysis of metastasis reveals an essential role for RhoC , 2000, Nature.

[17]  P. Steeg.  Tumor metastasis: mechanistic insights and clinical challenges , 2006, Nature Medicine.

[18]  Y. Lim,et al.  Syndecan-2 Mediates Adhesion and Proliferation of Colon Carcinoma Cells* , 2002, The Journal of Biological Chemistry.

[19]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[20]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[21]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[22]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[23]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[24]  A. Ballestrero,et al.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Anticancer Drugs to Overcome Chemoresistance in Antiapoptotic Bcl-2 Family Members Expressing Jurkat Cells , 2004, Clinical Cancer Research.

[25]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[26]  Paula D. Bos,et al.  Mediators of vascular remodelling co-opted for sequential steps in lung metastasis , 2007, Nature.

[27]  David A Hess,et al.  High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability , 2009, Journal of cellular and molecular medicine.

[28]  Robert A. Weinberg,et al.  Metastasis genes: A progression puzzle , 2002, Nature.

[29]  A. Harris,et al.  The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer , 2007, Cancer and Metastasis Reviews.

[30]  Joe W. Gray,et al.  Translating insights from the cancer genome into clinical practice , 2008, Nature.

[31]  L. Chin,et al.  Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene , 2006, Cell.

[32]  Y. Lim,et al.  Identification of a novel protein, LYRIC, localized to tight junctions of polarized epithelial cells. , 2004, Experimental cell research.

[33]  Robert Tibshirani,et al.  Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.

[34]  L. Sreerama,et al.  Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants , 2001, Cancer Chemotherapy and Pharmacology.

[35]  Lei Xu,et al.  GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[36]  H. Maeda,et al.  Antiapoptotic effect of haem oxygenase-1 induced by nitric oxide in experimental solid tumour , 2003, British Journal of Cancer.

[37]  Joel Greshock,et al.  High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization , 2005, Breast Cancer Research.

[38]  Christian A. Rees,et al.  Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[40]  P. Fisher,et al.  Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. , 2005, Gene.